10-Q/A: Allurion Restates Earnings, Faces Going Concern Doubt

Allurion Technologies, Inc. restated prior financial statements, revealing significant losses and material weaknesses in internal controls, while raising capital and addressing regulatory hurdles.

Summary

• Allurion Technologies, Inc. filed an amended quarterly report (10-Q/A) to restate its unaudited condensed consolidated financial statements for the quarters ended March 31, 2025, and March 31, 2024.
• The restatement was due to an error identified in historical financial statements, causing overstatements/understatements in comprehensive income, other income/expense, net income/loss, and accumulated deficit.
• The error originated from existing material weaknesses related to insufficient staff with public company and technical accounting experience and inadequate control activities.
• The restatement had no impact on revenue, gross profit, operating expenses, operating profit (loss), or cash and cash equivalents.
• For the three months ended March 31, 2025, the company reported a net loss of $1.501 million, a significant change from the previously reported net income of $7.379 million.
• Revenue decreased by 41% to $5.580 million for the three months ended March 31, 2025, compared to $9.386 million in the same period of 2024, primarily due to no sales in France and lower sales and marketing investment.
• Operating losses improved to $7.282 million for Q1 2025 from $11.390 million for Q1 2024, driven by reduced sales and marketing, and R&D expenses due to restructuring and trial completion.
• The company raised $14.5 million in net proceeds from equity offerings in Q1 2025, including private placements with RTW and Leavitt, and public offerings.
• Allurion announced topline results from its AUDACITY FDA pivotal trial, achieving the responder rate co-primary endpoint (58% lost >5% total body weight at 48 weeks) but missing the comparative co-primary endpoint.
• Sales of the Allurion Balloon in France resumed on February 13, 2025, after the French regulatory authority (ANSM) repealed its temporary suspension.
• The company is not in compliance with NYSE continued listing standards regarding minimum market capitalization and stockholders' equity, but its business plan to regain compliance has been accepted.
• Substantial doubt exists about the company's ability to continue as a going concern for the next year due to recurring losses and expected negative operating cash flows.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the significant financial restatement revealing a net loss instead of income, coupled with acknowledged material weaknesses in internal controls. The company explicitly states 'substantial doubt about its ability to continue as a going concern' and is non-compliant with NYSE listing standards. While capital was raised and French sales resumed, these positives are overshadowed by the severe financial and operational challenges, including a mandatory dilutive debt conversion triggered by low market capitalization.

Positives

• Operating loss improved to $7.282 million for the three months ended March 31, 2025, from $11.390 million in the prior year period.
• The AUDACITY FDA pivotal trial achieved its responder rate co-primary endpoint, with 58% of subjects losing more than 5% of their total body weight at 48 weeks.
• The rate of serious adverse events in the AUDACITY trial was low at 3.1%, the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon.
• Sales of the Allurion Balloon in France resumed on February 13, 2025, following the repeal of the temporary suspension by the ANSM after a successful remediation plan.
• The company successfully raised $14.5 million in net proceeds from equity offerings during Q1 2025, improving cash position to $20.408 million as of March 31, 2025.
• The company's business plan to regain compliance with NYSE listing standards has been accepted, allowing continued trading during the 18-month cure period.

Negatives

• The company restated previously issued financial statements, changing a reported net income of $7.379 million for Q1 2025 to a net loss of $1.501 million.
• The restatement was caused by material weaknesses in internal control over financial reporting, specifically a lack of sufficient staff with public company and technical accounting experience.
• Revenue decreased significantly by 41% to $5.580 million for the three months ended March 31, 2025, compared to $9.386 million in the same period of 2024.
• Net cash used in operating activities increased to $9.469 million for Q1 2025 from $8.636 million in Q1 2024.
• The company has an accumulated deficit of $223.708 million as of March 31, 2025, and expects to continue generating operating losses.
• Substantial doubt exists about the company's ability to continue as a going concern for the next year.
• The AUDACITY trial missed its comparative co-primary endpoint, with a 3.77% mean difference in total body weight loss compared to the pre-specified 3% superiority margin needed.
• The company is not in compliance with NYSE minimum market capitalization and stockholders' equity standards.
• A mandatory conversion of $5.0 million of RTW Convertible Notes was triggered on April 16, 2025, due to the company's market capitalization falling below $15.0 million, resulting in significant dilution (1,492,539 shares issued at $3.35/share).

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and expected negative operating cash flows.
• Potential inability to remain in compliance with certain financial covenants under credit facilities.
• Need for additional funding through equity or debt financings, with uncertainty regarding amount, timing, and favorable terms.
• Risk of significant delays, scaling back, or discontinuation of product development and commercialization if additional capital is not raised.
• Material weaknesses in internal control over financial reporting related to insufficient segregation of duties, lack of experienced staff, and insufficient information systems controls.
• Reliance on third parties for supply of parts and components, posing risk of supply chain disruption.
• Exposure to foreign currency exchange risk due to international operations, which could materially impact financial results.
• Risk of not gaining broader market acceptance for current and future products.
• Challenges in obtaining and maintaining timely regulatory approvals for products in new and existing markets.
• Fluctuations in financial results due to timing of orders, foreign currency exchange rates, selling days, product mix, and geographic mix.
• Potential for litigation or claims related to intellectual property, employee matters, securities class actions, or adverse patient reactions.

Future Outlook

The company expects to continue incurring net losses and negative operating cash flows for the foreseeable future as it focuses on obtaining regulatory approvals in new markets, refining sales and marketing strategies, and enhancing existing products. Additional costs associated with operating as a public company are also anticipated. The company plans to submit the fourth and final module of its premarket approval application to the FDA based on the AUDACITY trial results. Allurion OpCo is required to receive U.S. FDA marketing authorization for its product by June 30, 2026, as per the Omnibus Amendment. The company will need additional funding through equity or debt financings to support operations until it can generate sufficient revenue to achieve profitability.

Management Comments

• Management determined that the Error and related restatements were the result of existing material weaknesses in internal control over financial reporting, specifically the lack of sufficient levels of staff with public company and technical accounting experience to maintain proper control activities and perform risk assessment and monitoring activities.
• Management believes that the actions taken, including hiring additional accounting staff, implementing a new ERP system, and adding review controls, when complete, will be effective in remediating the material weaknesses.
• Management concluded that there is substantial doubt about the company's ability to continue as a going concern for a period of one year from the date the condensed consolidated financial statements are issued, citing recurring losses and expected continued operating losses.

Industry Context

Allurion operates in the highly competitive and rapidly changing weight loss and medical device industries. The company's Allurion Program, featuring a swallowable intragastric balloon and AI-powered remote patient monitoring, positions it in the non-surgical obesity treatment market. The launch of its VCS in the U.S. for patients using other weight loss treatments, including anti-obesity medications (GLP-1s) and bariatric surgery, indicates a strategy to integrate with broader weight management trends. The successful resumption of sales in France after regulatory suspension highlights the critical importance of regulatory compliance in the medical device sector. The company's financial struggles and need for continuous capital raises reflect the high R&D costs and market penetration challenges common in the medical device and biotech space, especially for novel technologies.

Comparison to Industry Standards

• The AUDACITY trial's 3.1% serious adverse event rate for the Allurion Balloon is reported as the lowest in a pivotal FDA trial for a liquid-filled intragastric balloon indicated for weight loss, suggesting a favorable safety profile compared to direct competitors in the intragastric balloon segment.
• The company's recurring losses and 'going concern' doubt are common for early-stage medical device companies focused on R&D and market penetration, but the magnitude of the restatement and the underlying internal control weaknesses are concerning and suggest a higher risk profile compared to more mature, well-governed industry peers.
• The significant revenue decline of 41% year-over-year, partly due to regulatory suspension in a key market (France), indicates vulnerability to market access challenges, which can be more pronounced for innovative devices requiring specific regulatory clearances and market acceptance compared to established medical products.
• The mandatory conversion of debt at a low share price due to market capitalization falling below a threshold is a strong indicator of financial distress and a less favorable financing outcome compared to companies with stronger market valuations and less restrictive debt covenants.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• RTW, a significant shareholder and director designator, is involved in multiple financing agreements: Revenue Interest Financing ($40.0 million proceeds), RTW Convertible Notes ($48.0 million proceeds), July 2024 Private Placement ($2.7 million purchase of Series A Preferred Stock and warrants), January 2025 Private Placement ($2.5 million purchase of Common Stock), and the New RIFA ($7.5 million additional revenue interest financing).
• A lease agreement for office space in Paris, France, with LNMP JPBC Invest, a related party (Company's then-Trade Marketing Director and former Chief Commercial Officer were involved), was terminated in February 2024.

Stakeholder Impact

• **Shareholders**: Significant negative impact due to restatement of financials, substantial dilution from multiple equity offerings and mandatory debt conversions at low prices, and ongoing 'going concern' doubt. NYSE non-compliance adds uncertainty to share liquidity and value.
• **Employees**: Impacted by restructuring efforts in November 2024, leading to lower headcount and severance costs.
• **Customers/Healthcare Providers**: Impacted by the temporary suspension and subsequent resumption of Allurion Balloon sales in France, affecting product availability and potentially trust.
• **Creditors (RTW)**: RTW has significant influence through various debt and financing agreements, including convertible notes and revenue interest financing, and has secured board representation. The mandatory conversion mechanism protects their investment by converting debt to equity at a low price if market cap falls.
• **Regulatory Authorities (FDA, ANSM, NYSE)**: The company is actively engaged with these bodies, addressing regulatory clearances (FDA PMA submission, ANSM re-clearance) and listing compliance (NYSE business plan), indicating ongoing scrutiny and compliance efforts.

Next Steps

• Submit the fourth and final module of the premarket approval application to the FDA based on AUDACITY trial results.
• Continue to implement and assess remediation measures for material weaknesses in internal control over financial reporting.
• Work to regain compliance with NYSE minimum market capitalization and stockholders' equity standards within the 18-month cure period.
• Allurion OpCo must receive Marketing Authorization from the U.S. FDA for commercialization of the Product in the United States no later than June 30, 2026.
• The company will be subject to quarterly monitoring for compliance with its business plan by the NYSE.
• RTW Convertible Notes purchasers have rights to convert additional principal amounts into shares of Common Stock under various conditions, including monthly conversion provisions up to $12.0 million by April 15, 2026.

Key Dates

Recommendation

The filing presents a highly concerning financial picture. The restatement of prior period net income to a net loss, coupled with acknowledged material weaknesses in internal controls, severely undermines financial credibility. The explicit 'going concern' doubt, significant revenue decline, and non-compliance with NYSE listing standards indicate severe operational and financial distress. While capital raises provide short-term liquidity, they are highly dilutive and occur at low valuations. The mandatory conversion of debt at a distressed price further signals a deteriorating financial position. These factors collectively point to substantial downside risk for investors, warranting a strong sell recommendation.

Keywords

Weight Loss, Medical Device, Intragastric Balloon, SEC Filing, Financial Restatement, Internal Controls, Going Concern, Capital Raise, Clinical Trials, FDA Approval, NYSE Listing, Allurion Balloon, Obesity Treatment, Corporate Governance, RTW Investments